https://www.biopharmawatch.com/news/ROIV/roivant-phase-2-phocus-study-results-ers-congress-2026 BiopharmaWatch en 2026-09-06T05:00:00.000Z Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call https://www.biopharmawatch.com/news/SYK/stryker-participate-2026-wells-fargo-healthcare-conference BiopharmaWatch en 2026-09-04T22:32:00.000Z Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference